🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the effort against drug-resistant strains of the infection, according to researchers.

A Worldwide Challenge

The sexually transmitted infection are increasing worldwide, with data suggesting over 82 million infections per year. Notably increased rates are reported in the African continent and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce treatment choices currently available.”

Health officials are increasingly worried about the rise in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". Ongoing monitoring showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Clearance

One new antibiotic, also known as Nuzolvence, was authorized by the US Food and Drug Administration in recent days for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers believe that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is additionally indicated for UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to develop it.

“This authorization marks a significant shift in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Testing Outcomes and Worldwide Availability

As per data detailed in a major medical journal, zoliflodacin successfully treated the vast majority of uncomplicated infections. This establishes an comparable level with the typical regimen, which combines a dual-drug approach. The trial included nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the ability to register and commercialise the drug in numerous developing nations.

Clinicians treating patients have shared hope. The availability of a easy-to-administer therapy like this is described as a "game-changer" for gonorrhoea control. This is considered vital to lessen the impact of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.